Merck & Co., Inc.

MRK

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
MRK
CIK0000310158
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033
Website merck.com
Phone908-740-4000
CEORobert M. Davis
Employees69,000

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$64.17 billion
Pre-Tax Income$19.94 billion
Net Income$17.13 billion
Net Income to Common$17.12 billion
EPS$6.74
View All
Balance Sheet
Cash$13.24 billion
Assets$117.11 billion
Liabilities$70.73 billion
Common Equity$46.31 billion
Liabilities & Equity$117.11 billion
View All
Cash Flow Statement
Calculations
NOPAT$17.11 billion
EBITDA$24.44 billion
Price to Earnings$12.29
Price to Book$4.54
ROE40.79%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months?

We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the […]

Article Link

Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other billionaire Cliff Asness’ stock picks with huge upside potential. Cliff Asness, the founder, managing principal, and chief investment officer […]

Article Link

Construction begins on MSD’s $1bn biologics centre in Delaware, US

The centre is said to become the future US production hub for Keytruda.

Article Link

How To Put $100 In Your Retirement Fund Each Month With Merck Stock

Merck (NYSE:MRK) operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The 52-week range of Merck stock price was $75.93 to $134.63. Merck's dividend yield is 4.06%. It paid $3.24 per share in dividends during the last 12 months. Don't Miss: Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share! Can you guess how many retire with a $5,

Article Link

Pfizer offers 'longer-term' opportunity amid tariff uncertainty

Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 billion in cost-cutting efforts, though the company says it's "unable to predict" the impact of US President Trump's tariffs. Guggenheim Securities senior research analyst and managing director Vamil Divan joins Brad Smith and Madison Mills on Morning Brief to take a closer look at Pfizer's earnings print. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Article Link